Short answer
Idexx Laboratories (IDXX) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.2B (up 9.9% year over year) with net income of $317M.
Q3 2026 key financials · XBRL
- Revenue
- $1.2B
- +9.9% YoY · −0.2% QoQ
- Net income
- $317M
- +15.5% YoY · −6.3% QoQ
- Operating margin
- 33.1%
- Gross margin
- 62.9%
- EPS (diluted)
- $4.01
- +17.9% YoY · −6.1% QoQ
Source: XBRL data from the Idexx Laboratories (IDXX) Q3 2026 10-Q on SEC EDGAR. USD.
Idexx Laboratories Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1.214B, up 9.9% YoY from $1.105B
- Operating margin 33.1% vs 32.1%; gross margin 62.9% vs 61.8%
- Best segment CAG: revenue $1.116B, up 10.2%; worst LPD: $34.8M, up 2.6%
- Operating cash flow $1.063B, up from $826.0M; cash $197.5M vs $180.1M
- 2026 capital expenditure plan approximately $160.0M; tariff, inflation, freight and supply-chain headwinds cited
Risk Factors
- No material changes from 2025 Annual Report risk factors
- Unknown or currently immaterial risks could materially adversely affect business, financial condition, or future results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Idexx Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.